Unknown

Dataset Information

0

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.


ABSTRACT: Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasm of young children initiated by mutations that deregulate cytokine receptor signaling. Studies of JMML are constrained by limited access to patient tissues. We generated induced pluripotent stem cells (iPSCs) from malignant cells of two JMML patients with somatic heterozygous p.E76K missense mutations in PTPN11, which encodes SHP-2, a nonreceptor tyrosine phosphatase. In vitro differentiation of JMML iPSCs produced myeloid cells with increased proliferative capacity, constitutive activation of granulocyte macrophage colony-stimulating factor (GM-CSF), and enhanced STAT5/ERK phosphorylation, similar to primary JMML cells from patients. Pharmacological inhibition of MEK kinase in iPSC-derived JMML cells reduced their GM-CSF independence, providing rationale for a potential targeted therapy. Our studies offer renewable sources of biologically relevant human cells in which to explore the pathophysiology and treatment of JMML. More generally, we illustrate the utility of iPSCs for in vitro modeling of a human malignancy.

SUBMITTER: Gandre-Babbe S 

PROVIDER: S-EPMC3682343 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.

Gandre-Babbe Shilpa S   Paluru Prasuna P   Aribeana Chiaka C   Chou Stella T ST   Bresolin Silvia S   Lu Lin L   Sullivan Spencer K SK   Tasian Sarah K SK   Weng Julie J   Favre Helene H   Choi John K JK   French Deborah L DL   Loh Mignon L ML   Weiss Mitchell J MJ  

Blood 20130425 24


Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasm of young children initiated by mutations that deregulate cytokine receptor signaling. Studies of JMML are constrained by limited access to patient tissues. We generated induced pluripotent stem cells (iPSCs) from malignant cells of two JMML patients with somatic heterozygous p.E76K missense mutations in PTPN11, which encodes SHP-2, a nonreceptor tyrosine phosphatase. In vitro differentiation of JMML iPSCs produc  ...[more]

Similar Datasets

| S-EPMC6942217 | biostudies-literature
| S-EPMC4618050 | biostudies-literature
| S-EPMC4297285 | biostudies-literature
| S-EPMC7802370 | biostudies-literature
| S-EPMC6286697 | biostudies-literature
| S-EPMC3975112 | biostudies-literature
| S-EPMC8305558 | biostudies-literature
| S-EPMC7153648 | biostudies-literature
| S-EPMC10533531 | biostudies-literature
| S-EPMC4626387 | biostudies-literature